Impact of high-throughput screening in biomedical research Table 2|Examples of recently approved drugs with origins in HTS hits* Drug(US trade name;company) Indication Target class Year HTS Year of FDA was run approval Gefitinib(Iressa:AstraZeneca) Cancer Tyrosine kinase c.1993 2003 Erlotinib (Tarceva;Roche) Cancer Tyrosine kinase c.1993 2004 Sorafenib(Nexavar;Bayer/Onyx Pharmaceutica 2.000.000 2005 Tipranavir(Aptivus;Boehringer Ingelheim) ☐2001 3 2005 Sitagliptin (Januvia;Merck 6 Co) ☐2005 0 2006 Dasatinib(Sprycel:Bristol-Myers Squibb) spunodwo5 1,500.000 ☐2009 2006 Maraviroc(Selzentry;:Pfizer) 2007 Lapatinib(Tykerb:GlaxoSmithKline) 1.000.000 3 2007 Ambrisentan(Letairis;Gilead) 5 2007 Etravirine(Intelence;Tibotec Pharmaceuticals) 2008 500.000 Tolvaptan(Samsca:Otsuka Pharmaceutical) 2009 Eltrombopag(Promacta;GlaxoSmithKline) 2008 G Company Figure 2|Size of corporate screening collec- tions over time.This figure shows that the screen- ing collections of four pharmaceutical companies from 2001 differ dramatically from those from 2009.Data taken from GlaxoSmithKline,Novartis, Sanofi-Aventis and Wyeth(now part of Pfizer). Macarron,R.NATURE REVIEWS DRUG DISCOVERY 10:188-195(2011) Impact of high-throughput screening in biomedical research Macarron, R. NATURE REVIEWS DRUG DISCOVERY 10: 188-195 (2011)